POSSIBLE INCREASED RISK OF RHABDOMYOLYSIS DURING CONCOMITANT USE OF SIMVASTATIN AND GEMFIBROZIL

Authors
VANPUIJENBROEK EP DUBUFVEREIJKEN PWG SPOOREN PFMJ VANDOORMAAL JJ
Citation
Ep. Vanpuijenbroek et al., POSSIBLE INCREASED RISK OF RHABDOMYOLYSIS DURING CONCOMITANT USE OF SIMVASTATIN AND GEMFIBROZIL, Journal of internal medicine, 240(6), 1996, pp. 403-404
Citations number
4
Categorie Soggetti
Medicine, General & Internal
Journal title
Journal of internal medicine → ACNP
ISSN journal
09546820
Volume
240
Issue
6
Year of publication
1996
Pages
403 - 404
Database
ISI
SICI code
0954-6820(1996)240:6<403:PIRORD>2.0.ZU;2-O
Abstract
The occurrence of rhabdomyolysis is one of the rare side-effects of th e cholesterol-lowering agent simvastatin. During the use of lovastatin , an agent related to simvastatin, the risk of this side-effect might be increased when cyclosporin or gemfibrozil are used concomitantly. I t is possible that this also applies for simvastatin. We present two p atients who developed rhabdomyolysis during the concomitant use of sim vastatin and gemfibrozil.